Table 3.
Alkaloid type | Alkaloids detected | Quantity of Alkaloid | Analytic technique | Ref |
---|---|---|---|---|
Batrachotoxins | BTX, BTXa, pBTX, hBTX | 28 mg hBTX, 43 mg BTX + pBTX + BTXa, 39 mg BTXa | HR-MS, NMR, UV, X-ray crystallography | (Tokuyama et al. 1968) |
Batrachotoxins | BTX, BTXa, BTXb, BTXc | 30 mg | NMR, IR, HR-MS | (Daly et al. 1965) |
Batrachotoxins | BTX, hBTX, BTXa, DQH (195B) | 500 ug BTX, 300 ug hBTX, | HRMS, GC–MS | (Myers et al. 1978) |
Batrachotoxins | BTX, BTXa, pBTX, hBTX | 20 ug BTX, 10 ug hBTX, 20 ug pBTX, 30 ug BTXa per skin | TLC, MS(EI), MS(CI), MS(quantitative), GC–MS, GC-FID | (Myers and Daly 1976a) |
Histrionicotoxins | HTX 283, isodihydroHTX 285, neodihydrohistrionicotoxin 285, allodihydrohistrionicotoxin 285, isotetradihydrohistrionicotoxin 287, tetrahydrohistrionicotoxin 287, octahydrohistrionicotoxin 291, HTX-D 287, HTX-267, HTX-259, HTX-239, Others: 219–1, 219–2, 223, 231, 235, 237, 239 243, 259, 283, 323 (maybe PTX-B) | 190 ug HTX 283, 290 ug isodihydroHTX 285, < 15 ug neodihydrohistrionicotoxin 285, > 15 ug allodihydrohistrionicotoxin 285, < 10 ug isotetradihydrohistrionicotoxin 287, < 5 ug tetrahydrohistrionicotoxin 287, < 10 ug octahydrohistrionicotoxin 291, 40 ug HTX-D 287, < 5 ug HTX-267, < 5 ug HTX-259, < 5 ug HTX-239 per skin | TLC, MS(EI), MS(CI), MS(quantitative), GC–MS, GC-FID | (Myers and Daly 1976a) |
Histrionicotoxins | HTX, dihydroisohistrionicotoxin | 53 mg HTX, 7 mg dihydroisohistrionicotoxin and 49 mg of other alkaloids | X-ray crystallography | (Daly et al. 1971) |
Pumiliotoxins | PTXa (307A, 307A”), PTXb (323A), DQH (195B) | 80 ug PTXa, 120 ug PTXb, 0–70 ug PTXc per skin | TLC, MS(EI), MS(CI), MS(quantitative), GC–MS, GC-FID | (Myers and Daly 1976a) |
Gephyrotoxins | GTX (called HTX-D) | Not reported | HR-MS, NMR | (Tokuyama et al. 1974) |
Gephyrotoxins | Gephyrotoxin and dehydrogephyrotoxin | Not reported | NMR, HR-MS, X-ray crystallography | (Daly et al. 1977) |
Pumiliotoxins | PTXa (307A, 307A”), PTXb (323A) | 1.5 mg PTXa, 1.5 mg PTXb | UV, NMR, IR, HR-MS | (Myers and Daly 1976b) |
Pumiliotoxins | PTX 251D, PTX 307A, PTX 323A | Not reported | X-ray crystallography, NMR | (Daly and Myers 1967) |
Pumiliotoxins | PTX 251D, PTX 307A’, PTX 307A” PTX 323A, alloPTX 267A, alloPTX 323B’, alloPTX 323B”, alloPTX 339A, alloPTX 339B | Not reported | NMR, IR | (Daly et al. 1980) |
Pumiliotoxins | 237A, 253, PTX-B(323-A), an isomer of PTX-B(323-B), 237B, 265 (degradation artifact?), 281A | 115 ug of 237A, 34 ug of 253, 8 ug of 323A, 3 ug of 323B, per 100 mg of skin | MS(CI), MS(EI), GC–MS | (Tokuyama et al. 1984) |
Allopumiliotoxins | alloPTX 253, alloPTX 267A, alloPTX 297A, alloPTX 323B | Not reported | NMR, HR-MS | (Daly et al. 1980) |
Homopumiliotoxins | hPTX 223G | 8 mg | HRMS, GC–MS, NMR | (Tokuyama et al. 1987) |
Decahydroquinolines | DQH (195B) | 17 mg PTXa, 20 mg PTXb, 16 mg PTXc | HR-MS, NMR, X-ray crystallography | (Daly et al. 1969) |
Pyrrolizidines | 223B, 223H, 237G, 251 K | Not reported | GC–MS(EI), GC–FTIR | (Garraffo et al. 1993) |
Indolizidines | 223AB, 239AB | Not reported | GC–MS(CI), GC–MS(EI), HR-MS | (Daly et al. 1978) |
Indolizidines | 223AB | Not reported | GC–MS and NMR of synthetic diastereoisomers | (Spande et al. 1981) |
2,5-disubstituted pyrrolidines |
197B | Not reported | GC–MS(CI-NH3), GC–MS(CI-ND3), GC-FID, GC-HRMS, NMR | (Daly et al. 1986) |
Lehmizidines | 275 | Not reported | GC–MS(CI-NH3), GC–MS(CI-ND3), GC-FID, GC-HRMS, NMR | (Daly et al. 1986) |
2,6-disubstituted piperidines | 225B | Not reported | GC–MS(CI-NH3), GC–MS(CI-ND3), GC-FID, GC-HRMS, NMR | (Daly et al. 1986) |
2,6-disubstituted piperidines | 241D | Not reported | GC–MS, NMR | (Edwards et al. 1988) |
Quinolizidines | 195C | Not reported | HR-MS, GC–MS(CI-NH3), GC–MS(EI), GC–FTIR | (Jones and Gorman 1999) |
Epibatidines | 208/210 Epibatidine | 60 mg | HR-MS, NMR, GC–FTIR | (Spande et al. 1992) |
Tetrodotoxins | TTX | Not reported | NMR, IR, TLC | (Mosher et al. 1964) |
Tetrodotoxins | TTX, 4-epiTTX, 4,9-anhydroTTX | Not reported | HPLC-FLD, TLC | (Daly et al. 1994a) |